使用SGLT2抑制剂可以减少持久性肺结节的进展和外科手术
Katherine Ortmeyer Welch1, Kelly A McGovern1, Lydia Chen1
1Division of Thoracic Surgery, Hospital of the University of Pennsylvania, Philadelphia 19104, PA, United States.
Lung cancer (Amsterdam, Netherlands)
|March 9, 2026
概括
-葡萄糖携带载体-2 抑制剂 (SGLT2i) 可能会减缓2型糖尿病患者早期肺癌结节的进展. 使用SGLT2i与结节生长风险降低和需要手术干预有关.
科学领域:
- 在瘤学瘤学.
- 内分泌学 在内分泌学.
- 肺部病理学 肺部病理学
背景情况:
- 在现场和早期的肺癌呈现为结节或磨砂玻璃不透明.
- 这些病变需要监测,许多病变进展,需要干预.
- 肺结节在瘤学中越来越令人担忧.
研究的目的:
- 调查-葡萄糖携带载体-2 抑制剂 (SGLT2i) 是否可以减缓早期肺癌的进展.
- 评估SGLT2i使用与肺结节进展和干预的速度之间的关联.
主要方法:
- 对6362名患者进行了回顾性队列研究,其中包括200名患有2型糖尿病 (T2DM) 和可疑肺结节的成年人.
- 根据暴露于SGLT2i或替代T2DM药物,患者被匹配.
- 主要结局包括结节的进展和干预的需要;使用多变量考克斯回归和日志等级测试进行分析.
主要成果:
- 使用SGLT2i与结进展率显著降低 (12%对24%,p=0.04).
- 调整后的分析显示,SGLT2i的使用降低了结节进展的风险 (HR=0.38),并延长了进展时间.
- 手术干预的频率较低 (3%对13%,p<0.01),并且在使用SGLT2i时干预的时间延长.
结论:
- 在T2DM患者中,SGLT2i的使用与肺结节进展和手术干预的风险较低有关.
- 这种效应似乎独立于并发症,血糖控制和基线结节大小.
- SGLT2i可能在控制持久性肺结节的生长方面发挥作用.
相关概念视频
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
568
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
568
01:26Mitral Stenosis III: Medical Management
399
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
399
01:27Pneumothorax-II
1.3K
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations:
1.3K